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ZebraﬁshAdenosine is an endogenous modulator of brain functions, which presents anticonvulsant properties. In addi-
tion, its levels can be increased during neural injury. The modulation of extracellular adenosine levels by
ectonucleotidase and adenosine deaminase (ADA) activities may represent a key mechanism in the control
of epileptogenesis. In the present study, we investigated the effects of acute seizure episodes and antiepileptic
drug (AED) treatments on ectonucleotidases and ADA activities in adult zebraﬁsh brain. Our data have dem-
onstrated that pentylenetetrazole (PTZ)-induced seizures did not alter ATP, ADP, and AMP hydrolysis in
brain membrane fractions. However, there was a signiﬁcant increase on ecto-ADA and soluble ADA activities
in PTZ-treated animals immediately after a clonus-like convulsion and loss of posture, which are typical be-
havioral changes observed in Stage 3. Furthermore, our results have demonstrated that AED pretreatments
prevented the stimulatory effect promoted by PTZ exposure on ADA activities. The PTZ and AED treatments
did not promote alterations on ADA gene expression. Interestingly, when exposed to PTZ, animals pretreated
with AEDs showed longer latency to reach the clonus-like seizure status, which is an effect that matches
the suppression of the increase of ADA activity promoted by the AEDs. These data suggest that the adenosine
deamination could be involved in the control of seizure development in zebraﬁsh and may be modulated by
AED treatments.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Epilepsy is one of themost commonneurological diseases character-
ized by recurrent and unpredictable seizures and affects approximately
50 million people worldwide. Despite its severity and common occur-
rence, the cellular and molecular basis of epilepsy is still largely un-
known (Banerjee et al., 2009; Elger and Schmidt, 2008). Moreover,
even with the diversity of antiepileptic drugs (AEDs) currently avail-
able, approximately 30% of patients with epilepsy still suffer from sei-
zures and the drugs that are offered nowadays are not completely
without side effects. Nevertheless, ongoing studies with animal modelspentin; AED, antiepileptic drug;
PTZ, pentylenetetrazole; PHT,
ontifícia Universidade Católica
-900, Porto Alegre, RS, Brazil.
vier OA license. have improved our understanding of the pathological basis of epilepsy,
providing considerable knowledge into the pharmacology of the drugs
employed to refrain seizures (Bialer and White, 2010). Zebraﬁsh is a
small freshwater teleost increasingly used as a model organism to un-
derstand the epilepsy mechanism. Several studies reported that PTZ-
induced seizures in zebraﬁsh larvae (Baraban et al., 2005) and adults
(Pineda et al., 2011; Wong et al., 2010) caused the behavioral and
electrographic alterations that would be expected from a seizure epi-
sode. Zebraﬁsh also show AEDs response, since chemically-induced
seizure-related behavioral alterations in larvae were suppressed by
AED pretreatments (Baraban et al., 2005; Berghmans et al., 2007).
Moreover, PTZ-induced seizures caused impairment in the passive
avoidance response by adult zebraﬁsh, which was suppressed by the
treatment with AED (Lee et al., 2010).
Adenosine is a purine nucleoside that can be released during neu-
ronal injury and has anticonvulsant properties, mediated mainly by
activation of adenosine A1 receptors (Boison, 2005). The antiepileptic
role of adenosine is based on the fact that adenosine A1 receptors are
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mate release, decreases glutamatergic responsiveness and hyperpo-
larizes neurons (for review, see Gomes et al., 2011). It has been
shown that brain extracellular adenosine levels increase during epi-
leptic seizures in animal models (Berman et al., 2000) and also in
patients with epilepsy (During and Spencer, 1992). Furthermore,
rats with chronic temporal lobe epilepsy have shown upregulation
of the adenosine A1 receptors (Ohta et al., 2010). A previous study ob-
served a decrease in adenosine deamination after 20 min of succes-
sive PTZ-induced seizures in zebraﬁsh, suggesting a modulation of
extracellular adenosine levels in the occurrence of repetitive seizures
(Siebel et al., 2011).
Besides the direct cellular adenosine release, ATP hydrolysis pro-
moted by a complex network of cell surface-located enzymes named
ectonucleotidases is another important source of extracellular adeno-
sine. ATP acts as an excitatory extracellular signal at the P2 receptor
subtypes, and then it is converted to the neuromodulator adenosine
through the action of ectonucleotidases. The ectonucleotidase pathway
modulates ATP and adenosine availability for activation of P2 and P1
receptor subtypes, respectively, which may represent an important
mechanism for epilepsy control (for review see Cognato and Bonan,
2010). Ectonucleotidases constitute an enzyme cascade system that
catalyzes the successive hydrolysis of purine and pyrimidine nucleo-
side tri-, di-, and monophosphates to their respective nucleosides
(Yegutkin, 2008). Tri- and diphosphonucleosides may be hydrolyzed
by ectonucleoside triphosphate diphosphohydrolase (E-NTPDase)
family members, whereas ecto-5′-nucleotidase hydrolyzes nucleoside
monophosphates producing adenosine. Adenosine is metabolized
by two possible pathways: deamination to inosine via adenosine
deaminase (ADA), and phosphorylation to AMP via adenosine kinase
(Boison et al., 2010). ADA is widely distributed among tissues and
body ﬂuids and catalyzes the hydrolytic deamination of adenosine to
inosine, both in the cytosol and in the cell membrane (Franco et al.,
1997; Maier et al., 2005). Ecto- and cytosolic-ADA activities and differ-
ent ADA-related gene expressions were already reported in zebraﬁsh
(Rosemberg et al., 2007, 2008). Moreover, biochemical and molecular
studies have also characterized NTPDase and ecto-5′-nucleotidase in
zebraﬁsh brain (Rico et al., 2003; Senger et al., 2004).
The involvement of ectonucleotidases and ADA pathway in epilepsy
and acute seizures has been reported in previous studies with rodents.
Changes in ectonucleotidase activities were not seen after a single
convulsant PTZ injection in rats. However, rats that weremore resistant
to seizure development presented increased ATP hydrolysis in synapto-
somes after PTZ-kindling (Bonan et al., 2000a, 2000b). Furthermore,
adult rats submitted to kainate-induced seizure in the neonatal period
showed increased ATP hydrolysis in hippocampal synaptosomes
(Cognato et al., 2011). Concerning the ADA activity, its inhibition effec-
tively reduced seizures in rodents (Dupere et al., 1999; Southam et al.,
2002). Furthermore, PTZ-kindled mice have shown increased adeno-
sine deamination in their brain tissue (Ilhan et al., 2005, 2006). Consid-
ering that zebraﬁsh have been reported as an effective model for
the study of epilepsy and that adenosine has evident anticonvulsant
effects, the investigation of the effects of acute seizures episodes and
antiepileptic drugs on ectonucleotidases and ADA in zebraﬁsh may im-
prove our knowledge on the role of adenosine in epilepsy. Therefore,
the aim of this study was to verify whether the antiepileptic drugs
phenytoin (PHT), gabapentin (GBP) and valproate (VPA) inﬂuence the
alterations promoted by PTZ-induced seizures on ectonucleotidase
and ADA pathways in zebraﬁsh brain.
2. Material and methods
2.1. Animals
Adult male and female wild type zebraﬁsh (Danio rerio) were
obtained from a local commercial supplier (Red Fish, RS, Brazil) andacclimated for 2 weeks before the experiments. The animals were
housed in a 50 L thermostated aquarium ﬁlled with unchlorinated
water constantly aerated at a targeted temperature of 26±2 °C. Fish
were kept under a 14–10 h light/dark cycle photoperiod and fed twice
a day with commercial ﬂake ﬁsh food supplemented with live brine
shrimp. The use andmaintenance of zebraﬁshwere done in accordance
with the “Guide for the Care and Use of Laboratory Animals” published
by the US National Institutes of Health and the experiments were
designed to minimize discomfort or suffering to the animals, as well
the number used. The protocol was approved by the Ethics Committee
of Pontiﬁcal Catholic University of Rio Grande do Sul (PUCRS) under
the number 11/00255-CEUA.
2.2. Materials
Trizma base, ammonium molybdate, polyvinyl alcohol, malachite
green, nucleotides, adenosine, EDTA, EGTA, sodium citrate, Coomassie
blue G, bovine serum albumin, calcium chloride, PHT, GBP, VPA and
PTZ were purchased from Sigma (St. Louis, MO, USA). Magnesium
chloride, phenol, and sodium nitroprusside were purchased from
Merck (Darmstadt, Germany). TRIzol®, SuperScript™ III First-Strand
Synthesis SuperMix, Taq Platinum, GelRed and Low DNAMass Ladder
were purchased from Invitrogen (Carlsbad, CA, USA). All other re-
agents used were from analytical grade.
2.3. PTZ model
To induce seizures, zebraﬁsh were individually exposed to 7.5 mM
PTZ in a 250 mL beaker. All PTZ treatments were videotaped and evalu-
ated later by trained observers. The seizure-like behavior was classiﬁed
according to each stage: stage I — dramatically increased swimming
activity, stage II — whirlpool swimming behavior, and stage III —
clonus-like seizures followed by loss of posture, when the animal falls
to one side and remains immobile for 1–3 s, as previously reported for
zebraﬁsh larvae (Baraban et al., 2005; Berghmans et al., 2007) and
adults (Wong et al., 2010). The animalswere submitted to the PTZ treat-
ment until they reached stage III. Early after reaching the stage III, each
animal was gently captured from the treatment beaker and used to per-
form biochemical and molecular analyses. Control group animals were
maintained in a 250 mL beaker with tank water for the same period
and conditions as the PTZ-treated groups. Before the PTZ exposure,
the animals remained exposed to AED treatments for 1 h, enough
time for all drugs to achieve seizure suppressor effect. PHT (450 μM),
GBP (50 mM) and VPA (3 mM) concentrations were chosen based on
previous studies (Baraban et al., 2005; Berghmans et al., 2007).
2.4. Preparation of soluble and membrane fractions
The animals were cryoanesthetized, euthanized by decapitation,
and brains were dissected (Wilson et al., 2009). Brain samples were
prepared as previously described and each independent experiment
was performed using biological preparations consisting of a “pool”
of ﬁve brains (Rico et al., 2003; Rosemberg et al., 2008; Senger
et al., 2004). Following the dissection, the whole zebraﬁsh brains
were homogenized in a glass-Teﬂon homogenizer according to the
protocol for each enzyme assay. For NTPDase and ecto-5′-nucleotidase
assays, zebraﬁsh brains were homogenized in 60 vol. (v/w) of chilled
Tris–citrate buffer (50 mM Tris–citrate, 2 mM EDTA, 2 mM EGTA,
pH 7.4). For ADA experiments, brains were homogenized in 20 vol.
(v/w) of chilled phosphate buffered saline (PBS), with 2 mM EDTA,
2 mMEGTA, pH 7.4. The brain membranes were obtained as previously
described (Barnes et al., 1993). The homogenates were centrifuged at
800×g for 10 min and the supernatant fraction was subsequently
centrifuged for 25 min at 40,000×g. The resultant supernatant and the
pellet obtained corresponded to the soluble and membrane fractions,
respectively. For soluble ADA activity experiments, the supernatant
Table 1
PCR primers design.
Enzymes Primer sequences (5′–3′) GenBank accession
number (mRNA)
β-Actin⁎ F-CGAGCTGTCTTCCCATCCA
R-TCACCAACGTAGCTGTCTTTCTG
ENSDART00000055194
EF1α⁎ F-CTGGAGGCCAGCTCAAACAT
R-ATCAAGAAGAGTAGTACCGCTAGCATTAC
NSDART00000023156
ADA1⁎⁎ F-GCACAGTGAATGAGCCGGCCAC
R-AATGAGGACTGTATCTGGCTTCAACG
BC076532.1
ADA2.1⁎⁎ F-TTCAACACCACACGTATCGGGCAC
R-ATCAGCACTGCAGCCGGATGATC
AF384217.1
ADA2.2⁎⁎ F-TTGCAATTGTTCATCATCCCGTAGC
R-TCCCGAATAAACTGGGATCATCG
XM_682627.1
⁎ According to Tang et al. (2007).
⁎⁎ Designed by authors.
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brane preparationswere frozen in liquid nitrogen, thawed, resuspended
in the respective buffers (to ensure the lysis of the brain vesicle mem-
branes) and centrifuged for 20 min at 40,000×g. The ﬁnal pellets were
resuspended and used for enzyme assays. All samples were maintained
at 2–4 °C throughout preparations.
2.5. Ectonucleotidase assays
NTPDase and 5′-nucleotidase assays were performed as previously
described methods (Rico et al., 2003; Senger et al., 2004). Zebraﬁsh
brain membranes (3–5 μg protein) were added to the reaction medi-
um containing 50 mM Tris–HCl (pH 8.0) and 5 mM CaCl2 (for the
NTPDase activity) or 50 mM Tris–HCl (pH 7.2) and 5 mM MgCl2
(for the 5′-nucleotidase activity) at a total volume of 200 μL. The sam-
ples were preincubated for 10 min at 37 °C and the reaction was
started by the addition of the substrate (ATP, ADP or AMP) to a ﬁnal
concentration of 1 mM. The reaction was terminated after 30 min
by the addition of trichloroacetic acid at a ﬁnal concentration of 5%,
and then the samples were chilled on ice for 10 min. The colorimetric
reagent composed by 2.3% polyvinyl alcohol, 5.7% ammoniummolyb-
date, and 0.08% malachite green was added (1 mL) in order to deter-
mine the inorganic phosphate released (Pi) (Chan et al., 1986).
The quantiﬁcation of Pi released was determined spectrophotometri-
cally at 630 nm and the speciﬁc activity was expressed as nmol of
Pi·min−1 mg−1 of protein. Controls with the addition of the enzyme
preparation after the addition of trichloroacetic acid were used to cor-
rect non-enzymatic hydrolysis of the substrates. All enzyme reactions
were performed in triplicate.
2.6. Adenosine deaminase assays
Ecto- and cytosolic-ADA activities were determined as previously
described (Rosemberg et al., 2008). The brain fractions (5–10 μg pro-
tein) were added to the reaction mixture containing 50 mM sodium
phosphate buffer (pH 7.0) and 50 mM sodium acetate buffer (pH 5.0)
for soluble and membrane fractions, respectively, in a ﬁnal volume
of 200 μL. The samples were preincubated for 10 min at 37 °C and the
reaction was started by the addition of substrate (adenosine) to a ﬁnal
concentration of 1.5 mM. The reaction was stopped by the addition of
500 μL phenol-nitroprusside reagent (50.4 mg of phenol and 0.4 mg
of sodium nitroprusside/ml) after 75 min (soluble fraction) and
120 min (membrane fraction). ADA activity was determined spectro-
photometrically by measuring the ammonia produced over a ﬁxed
time interval using a Berthelot reaction according to Weisman et al.
(1988). The reaction mixtures were mixed to 500 μL of alkaline-
hypochlorite reagent (sodium hypochlorite to 0.125% available chlo-
rine, in 0.6 M NaOH) and vortexed. Samples were incubated at 37 °C
for 15 min and the colorimetric assay was carried out at 635 nm. The
ADA activity was expressed as nmol of NH3·min−1 mg−1 of protein.
Controls with the addition of the enzyme preparation after mixing
with phenol-nitroprusside reagent were used to correct the substrates'
non-enzymatic hydrolysis. All enzyme reactions were performed in
triplicate.
2.7. Protein determination
Protein was measured by the Coomassie blue method (Bradford,
1976) using bovine serum albumin as a standard.
2.8. Gene expression analysis
The expression of ADA-related genes ada1, ada2.1, and ada2.2was
analyzed by quantitative real time RT-PCR (RT-qPCR). Total zebraﬁsh
brain RNA was isolated using TRIzol® reagent (Invitrogen, USA)
according to the manufacturer's instructions. The RNA purity wasquantiﬁed spectrophotometrically calculating the ratio between absor-
bance values at 260 and 280 nm. Afterwards, cDNA was synthesized
with ImProm-II™ Reverse Transcription System (Promega) from 1 μg
of total RNA, according to the supplier's instructions.
Quantitative PCR was performed using SYBR® Green I (Invitrogen)
to detect double-strand cDNA synthesis. Reactions were done in a vol-
ume of 25 μL using 12.5 μL of diluted cDNA (1:50), containing a ﬁnal
concentration of 0.2× SYBR® Green I (Invitrogen), 100 μM dNTP, 1×
PCR Buffer, 3 mM MgCl2, 0.25 U Platinum® Taq DNA Polymerase
(Invitrogen) and 200 nM of each reverse and forward primers
(Table 1). The PCR cycling conditionswere: an initial polymerase activa-
tion step for 5 min at 95 °C, 40 cycles of 15 s at 95 °C for denaturation,
35 s at 60 °C for annealing and 15 s at 72 °C for elongation. At the end
of cycling protocol, a melting-curve analysis was included and ﬂuores-
cence measured from 60 to 99 °C. Relative expression levels were
determined with 7500 Real-Time System Sequence Detection Software
v.2.0.5 (Applied Biosystems). The efﬁciency per sample was calculated
using LinRegPCR 11.0 Software (http://LinRegPCR.nl) and the stability
of the references genes, EF1α, and β-actin (M-value) and the optimal
number of reference genes according to the pair wise variation (V)
were analyzed by GeNorm 3.5 Software (http://medgen.ugent.be/
genorm/). Relative RNA expression levels were determined using the
2−ΔΔCT method.
2.9. Statistical analysis
The results are expressed as mean±S.D. The behavioral data were
analyzed by one-way ANOVA followed by Duncan post-hoc test. The
enzymatic and molecular data were analyzed by two-way ANOVA
followed by Duncan post-hoc test. Pb0.05 was considered as signiﬁ-
cant. All data were evaluated with SPSS 18.0 for Windows.
3. Results
3.1. Behavioral seizure parameters in adult zebraﬁsh
Behavioral seizure parameters were evaluated in adult zebraﬁsh
exposed to PTZ, which have shown a sequence of progressive behav-
ioral changes classiﬁed in stage I, II, and III. The latencies to the ﬁrst
episodes of the seizure activity in stages I, II, and III were analyzed
for each animal during PTZ exposure. The seizure-related behavioral
alterations observed in animals treated with PTZ were suppressed
by their pretreatment with the antiepileptic drugs PHT, GBP, and
VPA. The animals exposed to PTZ without AED pretreatments have
shown the ﬁrst features of stage I at 50±6.6 s, whereas the animals
pretreated with PHT, GBP and VPA have shown the ﬁrst episode of
stage I at 87.3±64.72, 80.5±35.65 and 91.8±24.2 s, respectively.
Stage II was observed at 125.8±30.95, 157.6±67.1, 154.1±73.99
and 155.1±38.88 s in PTZ, PHT, GBP and VPA groups, respectively.
Table 2
Effect of PTZ treatment on ectonucleotidase activities in adult zebraﬁsh brain membranes.
Group n ATP hydrolysis ADP hydrolysis AMP hydrolysis
Control 5 328.3±33.5 122.2±48.5 11.1±2.5
PTZ 7.5 mM 5 313.2±47.3 133.5±40.6 9.6±1.7
The nucleotide hydrolysis was expressed as nmol Pi·min−1 mg−1 protein.
Data are expressed as mean±S.E.M.
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137.5±13.92 (without pretreatment), 268.2±98.6 (pretreated with
PHT), 253.7±90.49 (pretreatedwithGBP) and 240±38.63 s (pretreated
with VPA) (F(3,23)=4.31; Pb0.05). Our results have demonstrated that
commonly used antiepileptic drugs signiﬁcantly increased the latency to
clonus-like convulsions in adult zebraﬁsh (Fig. 1).
3.2. Nucleotide and nucleoside hydrolysis in zebraﬁsh brain during
PTZ-induced acute seizure
The effect of PTZ-induced acute seizure was tested on NTPDase,
ecto-5′-nucleotidase, and ADA activities in adult zebraﬁsh brain. The
animals remained exposed to PTZ treatment until they reached the
stage III, when the animal falls to one side and remains immobile
for 1–3 s. Our results have demonstrated that PTZ-induced seizures
did not alter ATP, ADP, and AMP hydrolysis in zebraﬁsh brain mem-
branes (Table 2). Nevertheless, PTZ treatment signiﬁcantly increased
ecto-ADA and soluble-ADA activities (Fig. 2). Our results have dem-
onstrated that PHT (membrane: F(3,31)=3.45, Pb0.05; soluble:
F(3,15)=0.44, Pb0.0001), GBP (membrane: F(3,15)=3.87, Pb0.05;
soluble: F(3,15)=5.98, Pb0.05), and VPA (membrane: F(3,23)=3.18,
Pb0.05; soluble: F(3,15)=5.01, Pb0.05) pretreatments prevented the
stimulatory effect promoted by acute PTZ-induced seizures on ADA ac-
tivity. The AED treatments themselves did not alter the ecto-ADA and
soluble ADAactivity (Fig. 2). Quantitative real timeRT-PCR experiments
were performed to verify whether the PTZ and AED treatments have
altered the expression of ADA-related genes. There were no changes
on ada1, ada2.1, and ada2.2 gene expression after all treatments tested
in zebraﬁsh brain (Fig. 3).
4. Discussion
In the present study, we evaluated the effects of acute seizures
episodes and AED treatments on ectonucleotidases and ADA activities
in zebraﬁsh. Our ﬁndings have demonstrated that soluble and ecto-
ADA activities were increased in zebraﬁsh brain after an acute seizure
episode, an effect that was suppressed by the antiepileptic drug pre-
treatment. NTPDase and 5′-nucleotidase activities have not shown
signiﬁcant alterations after seizure occurrence.
Adenosine is an endogenous modulator of brain functions with
antiepileptic actions, mainly due to the enhanced presence of adeno-
sine A1 receptors in excitatory synapses, where they inhibit the
release of glutamate, decrease glutamatergic responsiveness and
hyperpolarize neurons (for review see Gomes et al., 2011). Besides
the cell adenosine release, ATP release and its degradation into aden-
osine via ectonucleotidases are a signiﬁcant source of extracellular
adenosine. Under physiological conditions, astrocytic release of ATPFig. 1. Latency to the ﬁrst episode of the three different seizure behavioral stages in
zebraﬁsh. Bars represent the mean±S.D. from 6 animals for each group. The symbol
(*) represents a signiﬁcant difference from stage III PTZ group (one-way ANOVA,
followed by Duncan test as post hoc, P≤0.05).followed by its degradation to adenosine via ectonucleotidases is a
major source of adenosine (Pascual et al., 2005). In epileptic patients,
a signiﬁcant increase of soluble nucleotidase activity in blood serum
was observed following a seizure episode (Grosso et al., 2009). More-
over, serum ATP, ADP, and AMP hydrolysis rates were increased in
rats after a single PTZ-induced seizure episode (Bruno et al., 2002).
It is possible to hypothesize that the higher serum nucleotidase activ-
ity and the possible increase in adenosine levels could represent an
important mechanism in the modulation of epileptic events (Bruno
et al., 2002; Grosso et al., 2009). Our present study shows that
ectonucleotidase activities in zebraﬁsh brain membranes were not
altered upon a single acute seizure induced by PTZ. Similar results
were observed after successive seizure episodes in zebraﬁsh, with
no differences in ATP, ADP, and AMP hydrolysis in brain membranes
(Siebel et al., 2011). Adult rats submitted to kainic acid-inducedFig. 2. Effect of the antiepileptic drugs PHT (A), GBP (B) and VPA (C) and PTZ treatments
on membrane-bound and soluble ADA activity from zebraﬁsh brain. Bars represent the
mean±S.D. from 6 different experiments. The symbols (*, #) represent a signiﬁcant dif-
ference from control and AED+PTZ group, respectively (two-way ANOVA, followed by
Duncan test as post hoc, P≤0.05). The speciﬁc enzyme activity is expressed as nmol of
NH3·min−1 mg−1 of protein.
Fig. 3. Effect of PHT, GBP, VPA and PTZ treatments on ADA gene expression pattern. The
ﬁgures show the expression patterns of ada1 (A), ada2.1 (B) and ada2.2 (C), in adult
zebraﬁsh brain. The results were expressed as mean±S.D. of four independent exper-
iments performed in quadruplicate.
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sis when compared to control animals. However, 12 h after the sei-
zure, ATP hydrolysis was not signiﬁcantly changed (Cognato et al.,
2011). Furthermore, there were no differences on ectonucleotidase
activities after a single PTZ exposure in rats. However, rats that were
more resistant to seizures showed increased ATP hydrolysis after
PTZ-kindling treatment (Bonan et al., 2000b). These ﬁndings suggest
that acute seizure episodes are not able to alter ectonucleotidase activ-
ities, which are subject to late and prolonged alterations after recurrent
seizures (Bonan et al., 2000a), as a consequence of an adaptive
plasticity.During seizures, brain extracellular concentrations of adenosine
increase to levels that suppress epileptic activity in animal models
and also in patients with epilepsy (Dunwiddie and Masino, 2001).
Hippocampal adenosine levels were increased in rats submitted to
seizures induced by bicuculline, kainate, and PTZ (Berman et al.,
2000). During and after single spontaneous seizure episodes, humans
with intractable complex partial epilepsy showed increased hippo-
campal extracellular adenosine range. In each patient, adenosine
levels increased during the spontaneous seizure and remained elevated
above basal values after the occurrence (During and Spencer, 1992). As
previously reported, besides the cell uptake through bi-directional
nucleoside transporters and phosphorylation to AMP by adenosine ki-
nase, extracellular adenosine concentrations can be regulated through
its deamination by ADA (Fredholm et al., 2005). ADA has an important
role in the regulation of the extracellular adenosine concentration.
Studies have reported that the inhibition of adenosine deamination ef-
fectively reduced seizures in diverse animal epilepsy models (Dupere
et al., 1999; Southam et al., 2002).
In mice, seizures induced by a single or repeated PTZ doses cause
rapid and signiﬁcant increase in the density of ADA in several brain
areas. The results have shown that after a single generalized convul-
sive seizure, ADA levels were higher than in the kindled animals,
which presented several seizures (Pence et al., 2009). A previous
study with zebraﬁsh reported a decrease in ecto-ADA activity after
20 min of successive PTZ-induced seizure episodes (Siebel et al.,
2011). In the present study, we showed that the soluble and ecto-
ADA activities were increased at the ﬁrst clonic-seizure episode in-
duced by PTZ exposure. Our results demonstrate, for the ﬁrst time,
that ADA activity is early increased after a single seizure occurrence
in zebraﬁsh, suggesting a decreased extracellular adenosine levels
during this period.
In this study, we have tested classical AEDs, such as PHT, GBP and
VPA, which act through a variety of mechanisms, often suppressing ion
channels, promoting gabaergic neurotransmission and/or decreasing
glutamatergic neurotransmission. These drugs have been used for the
treatment of epilepsy and partial and generalized tonic–clonic seizures
(Brodie, 2010). Previous studies have also demonstrated that these
drugs can interfere in the purinergic system (Borowicz et al., 1997,
2002; Cognato et al., 2007; Siebel et al., 2011). Our results have shown
that antiepileptic drug treatments suppress the seizure-induced increase
in ADA activity. This suppression of the increased ADA activity coincides
with the longer latency to reach the stage III of seizure status showed by
animals pretreatedwith antiepileptic drugs. The animals pretreatedwith
PHT, GBP and VPA spent more time to reach the clonic-like seizure stage
when compared with animals without AED pretreatments. In mice, the
PTZ-induced increase in ADA activity was suppressed by glutathione
treatment (Pence et al., 2009). Studies have shown that glutathione
has anticonvulsant effect, and these results suggest that a possible
ADAmodulation is involved in the anticonvulsant activity of glutathione
(Pence et al., 2009). In addition, the VPA treatment suppressed the
PTZ-kindling-induced increase in ADA activity in mice brain tissue
(Ilhan et al., 2005, 2006).
In zebraﬁsh brain, ADA is located both in the cytosol and in the
cell membrane and the regulation of brain adenosine levels might
be promoted by distinct ADA members. A previous study character-
ized these ADA members, which have shown diverse gene expression
patterns and activity properties (Rosemberg et al., 2007, 2008). The
ADA1 member is a typical cytosolic enzyme that also acts as an
ecto-ADA, cleaving extracellular adenosine. The ADA2 enzyme seems
to act speciﬁcally in the extracellular fraction (Zavialov and Engström,
2005; Zavialov et al., 2010). Previous studies suggest that ecto-ADA
has extra-enzymatic and co-stimulatory functional roles. There is evi-
dence that ecto-ADA is bound with adenosine receptors, modulating
their afﬁnity (Ciruela et al., 1996; Herrera et al., 2001; Saura et al.,
1998). In this study, we showed that one single seizure episode sig-
niﬁcantly increased cytosolic and ecto-ADA activity in zebraﬁsh brain,
25A.M. Siebel et al. / Pharmacology, Biochemistry and Behavior 104 (2013) 20–26effect that was suppressed by antiepileptic drug pretreatments. How-
ever, successive convulsive episodes decreased the ecto-ADA activity,
whereas they did not change adenosine deamination in the soluble
fraction (Siebel et al., 2011). These results have shown that ADA ac-
tivities are differently modulated early after a single seizure or suc-
cessive seizure episodes. The expression proﬁle of ADA related
genes (ada1, ada2.1 and ada2.2) in zebraﬁsh brain was previously
reported (Rosemberg et al., 2007). Our present RT-PCR results
showed that single seizure episodes did not alter the ADA-related
genes expression, similarly to our previous study, which showed no
alteration after successive seizure episodes (Siebel et al., 2011). In
view of the fact that the observed alterations in ADA activity were
not caused by modiﬁcations in the transcriptional pattern of ADA
family enzymes, we suggest that these changes could be attributed
to seizure effects on the post-translational modulation of these en-
zymes. According to a previous study, ADA-related enzymes present
putative regulatory sites for posttranslational mechanisms, such
as phosphoylation/desphosphorylation (Rosemberg et al., 2007).
Therefore, further studies are necessary to characterize the post-
translational mechanisms involved in the ADA activity modulation
process in zebraﬁsh.
Nowadays, zebraﬁsh are being increasingly used in epileptic seizure
research.When exposed to convulsant agents, zebraﬁsh show behavioral
and electrographic alterations characteristic of seizure episodes (Baraban
et al., 2005; Pineda et al., 2011; Wong et al., 2010) and AED response
(Baraban et al., 2005; Berghmans et al., 2007). Furthermore, since caf-
feine, a nonselective adenosine antagonist, induced seizure-like behavior
episodes in zebraﬁsh, it is possible to suggest that adenosine signaling is
associated to epilepsy in zebraﬁsh (Wong et al., 2010). Our ﬁndings
showed that antiepileptic drug pretreatments suppress the increase
in adenosine deamination, which coincides with a longer period to
reach the clonic-seizure status. Our results suggest that the adenosine de-
amination system is involved in the control of seizure occurrences in
zebraﬁsh. Furthermore, our study contributes to elucidating the mecha-
nisms underlying the modulator effects in adenosine signaling during
the occurrence of seizures in this specie.Acknowledgments
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